HTF Market Report released a new research document of 512 pages on industry titled as ‘Non-Alcoholic Steatohepatitis (NASH) – Pipeline Review, H1 2018’ with detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes regions and important players/vendors such as AdAlta Ltd, Albireo Pharma Inc, Allergan Plc, Amunix Operating Inc The report will help you gain market insights, future trends and growth prospects for forecast period of 2018-23
Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. Symptoms of NASH include fatigue, weight loss for no clear reason, general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome.
Request a sample report @ https://www.htfmarketreport.com/sample-report/896019-non-alcoholic-steatohepatitis-1
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Non-Alcoholic Steatohepatitis (NASH) – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis (NASH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 32, 28, 6, 84, 35 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.
Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal).
– The pipeline guide reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal)
Get Customization in the Report, Enquire Now @ https://www.htfmarketreport.com/enquiry-before-buy/896019-non-alcoholic-steatohepatitis-1
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/896019-non-alcoholic-steatohepatitis-1
Companies Mentioned in the Report
AdAlta Ltd, Albireo Pharma Inc, Allergan Plc, Amunix Operating Inc, Aquinox Pharmaceuticals Inc, Arcturus Therapeutics Ltd, Ardelyx Inc, Arisaph Pharmaceuticals Inc, Assembly Biosciences Inc, AstraZeneca Plc, BASF SE, Betagenon AB, Bird Rock Bio Inc, BLR Bio LLC, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co, Cadila Healthcare Ltd, Can-Fite BioPharma Ltd, Cardax Inc, Carmot Therapeutics Inc, Catabasis Pharmaceuticals Inc, Cerenis Therapeutics Holding SA, ChemoCentryx Inc, CohBar Inc, Connexios Life Sciences Pvt Ltd, ConSynance Therapeutics Inc, CymaBay Therapeutics Inc, Daiichi Sankyo Co Ltd, Debiopharm International SA, Dicerna Pharmaceuticals Inc, Dimerix Bioscience Pty Ltd, Dong-A Socio Holdings Co Ltd, DURECT Corp, Eli Lilly and Co, Enanta Pharmaceuticals Inc, Enyo Pharma SA, Exicure Inc, Forma Therapeutics Inc, Galectin Therapeutics Inc, Galecto Biotech AB, Galmed Pharmaceuticals Ltd, Gemphire Therapeutics Inc, Genfit SA, GenKyoTex SA, Gilead Sciences Inc, GlaxoSmithKline Plc, GRI Bio Inc, Guangdong Zhongsheng Pharmaceutical Co Ltd, Hanmi Pharmaceuticals Co Ltd, HemoShear Therapeutics, LLC, iCo Therapeutics Inc., Immuron Ltd, Intercept Pharmaceuticals Inc, Inventiva, Ionis Pharmaceuticals Inc, Kissei Pharmaceutical Co Ltd, Kyorin Pharmaceutical Co Ltd, Madrigal Pharmaceuticals Inc., Matinas BioPharma Holdings Inc, MedImmune LLC, Merck & Co Inc, Metacrine Inc, Mitsubishi Tanabe Pharma Corp, Naia Ltd, NeuroVive Pharmaceutical AB, NGM Biopharmaceuticals Inc, Nippon Chemiphar Co Ltd, Novartis AG, NovaTarg Therapeutics Inc, Novo Nordisk AS, Nuevolution AB, Ocera Therapeutics Inc, Oramed Pharmaceuticals Inc, Pfizer Inc, Pharmaxis Ltd, Promethera Biosciences SA, ProMetic Life Sciences Inc, Protalix BioTherapeutics Inc, Redx Pharma Plc, Regulus Therapeutics Inc, reMYND NV, Ritter Pharmaceuticals Inc, Saje Pharma LLC, Sancilio & Company Inc, Sanofi, Second Genome Inc, Seres Therapeutics Inc, Shenzhen HighTide Biopharmaceutical Ltd, Shire Plc, Sprint Bioscience AB, Synlogic Inc, TaiwanJ Pharmaceuticals Co Ltd, Tiziana Life Sciences Plc, TRACON Pharmaceuticals Inc, Translate Bio Inc, Vascular Biogenics Ltd, Verlyx Pharma Inc, Viking Therapeutics Inc, Zebra Discovery Ltd
Table of Contents
Table of Contents 2
Non-Alcoholic Steatohepatitis (NASH) – Overview 8
Non-Alcoholic Steatohepatitis (NASH) – Therapeutics Development 9
Non-Alcoholic Steatohepatitis (NASH) – Therapeutics Assessment 31
Non-Alcoholic Steatohepatitis (NASH) – Companies Involved in Therapeutics Development 47
Non-Alcoholic Steatohepatitis (NASH) – Drug Profiles 91
Non-Alcoholic Steatohepatitis (NASH) – Dormant Projects 478
Non-Alcoholic Steatohepatitis (NASH) – Discontinued Products 481
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Number of Products by Stage and Tar
It’s vital you keep your market knowledge up to date. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide customization accordingly.
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=896019
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218